Committee for Orphan Medicinal Products (COMP)
Draft agenda for the meeting on 16-18 July 2024

Chair: Violeta Stoyanova-Beninska
16 July 2024, 08:30-19:30, virtual meeting room
17 July 2024, 08:30-19:30, virtual meeting room
18 July 2024, 08:30-17:00, virtual meeting room

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction ................................................................. 5
  1.1. Welcome and declarations of interest of members and experts .......... 5
  1.2. Adoption of agenda ...................................................... 5
  1.3. Adoption of the minutes ................................................. 5

2. Applications for orphan medicinal product designation .................. 5
  2.1. For opinion ........................................................................ 5
    2.1.1. EMA/OD/0000159992 .................................................. 5
    2.1.2. EMA/OD/0000173345 .................................................. 5
    2.1.3. EMA/OD/0000173347 .................................................. 5
    2.1.4. EMA/OD/0000169543 .................................................. 5
    2.1.5. EMA/OD/0000164952 .................................................. 5
    2.1.6. EMA/OD/0000172086 .................................................. 6
    2.1.7. EMA/OD/0000166750 .................................................. 6
    2.1.8. EMA/OD/0000165577 .................................................. 6
  2.2. For discussion / preparation for an opinion .................................. 6
    2.2.1. EMA/OD/0000154786 .................................................. 6
    2.2.2. EMA/OD/0000155550 .................................................. 6
    2.2.3. EMA/OD/0000160667 .................................................. 6
    2.2.4. EMA/OD/0000167672 .................................................. 6
    2.2.5. EMA/OD/0000168913 .................................................. 6
    2.2.6. EMA/OD/0000168919 .................................................. 6
    2.2.7. EMA/OD/0000168961 .................................................. 7
    2.2.8. EMA/OD/0000169888 .................................................. 7
    2.2.9. EMA/OD/0000170073 .................................................. 7
    2.2.10. EMA/OD/0000171663 ............................................... 7
    2.2.11. EMA/OD/0000171786 ............................................... 7
    2.2.12. EMA/OD/0000173551 ............................................... 7
    2.2.13. EMA/OD/0000174349 ............................................... 7
    2.2.14. EMA/OD/0000174573 ............................................... 7
    2.2.15. EMA/OD/0000178304 ............................................... 7
    2.2.16. EMA/OD/0000178496 ............................................... 8
    2.2.17. EMA/OD/0000178582 ............................................... 8
    2.2.18. EMA/OD/0000179126 ............................................... 8
    2.2.19. EMA/OD/0000179366 ............................................... 8
    2.2.20. EMA/OD/0000179561 ............................................... 8
    2.2.21. EMA/OD/0000183012 ............................................... 8
2.2.22. - EMA/OD/0000171163 .......................................................... 8
2.3. Revision of the COMP opinions ...................................................... 8
2.4. Amendment of existing orphan designations ..................................... 8
2.5. Appeal ............................................................................................ 9
2.6. Nominations .................................................................................... 9
2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs ............................................................. 9
2.7. Evaluation on-going ......................................................................... 9

3. Requests for protocol assistance with significant benefit question 9
3.1. Ongoing procedures .......................................................................... 9
3.1.1. - ........................................................................................................ 9
3.1.2. - ........................................................................................................ 9
3.1.3. - ........................................................................................................ 9
3.1.4. - ........................................................................................................ 9
3.1.5. - ........................................................................................................ 9

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation 10
4.1. Orphan designated products for which CHMP opinions have been adopted .... 10
4.1.1. - odronextamab - EMEA/H/C/006215 ......................................................... 10
4.1.2. Tepkingly - epocritamab - EMEA/H/C/005985/II/0001, EU/3/22/2634, EMA/OD/0000157895 ................................................................. 10
4.2. Orphan designated products for discussion prior to adoption of CHMP opinion .... 10
4.2.1. - elafibranor - EMEA/H/C/006231/0000, EU/3/19/2182, EMA/OD/0000173044 .......... 10
4.2.2. - chimeric monoclonal antibody against claudin-18 splice variant 2 - EMEA/H/C/005868, EU/3/10/803, EMA/OD/0000166702 ........... 10
4.3. Appeal ............................................................................................. 10
4.4. On-going procedures ....................................................................... 10
4.5. Orphan Maintenance Reports .......................................................... 11

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension 11
5.1. After adoption of CHMP opinion ....................................................... 11
5.2. Prior to adoption of CHMP opinion ................................................... 11
5.2.1. Lutathera - lutetium ($^{177}$Lu) oxodotreotide - EMEA/H/C/004123/II/0052, EU/3/07/523 .... 11
5.2.2. Ngenla - somatrogon - EMEA/H/C/005633/II/0016, EU/3/12/1087 ......................... 11
5.3. Appeal ............................................................................................. 11
5.4. On-going procedures ....................................................................... 11

6. Application of Article 8(2) of the Orphan Regulation 11
7. Organisational, regulatory and methodological matters 11
7.1. Mandate and organisation of the COMP ............................................ 11
7.1.1. COMP membership
7.1.2. Vote by proxy
7.1.3. Strategic Review & Learning meetings - Hungary
7.1.4. Protocol Assistance Working Group (PAWG)
7.1.5. COMP Decisions Database

7.2. Coordination with EMA Scientific Committees or CMDh-v
7.2.1. Recommendation on eligibility to PRIME – report

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups
7.3.1. Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)
7.3.2. Upcoming ITF meetings

7.4. Cooperation within the EU regulatory network
7.4.1. European Commission

7.5. Cooperation with International Regulators
7.5.1. Food and Drug Administration (FDA)
7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
7.5.3. Therapeutic Goods Administration (TGA), Australia
7.5.4. Health Canada

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

7.7. COMP work plan

7.8. Planning and reporting
7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2024
7.8.2. Overview of orphan marketing authorisations/applications

8. Any other business
8.1. EMA business Pipeline activity

9. Explanatory notes
1. **Introduction**

1.1. **Welcome and declarations of interest of members and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 16-18 July 2024. See July 2024 COMP minutes (to be published post September 2024 COMP meeting).

1.2. **Adoption of agenda**

COMP agenda for 16-18 July 2024.

1.3. **Adoption of the minutes**

COMP minutes for 18-20 June 2024.

2. **Applications for orphan medicinal product designation**

2.1. **For opinion**

2.1.1. - EMA/OD/0000159992

   Treatment of acute lymphoblastic leukaemia

   **Action:** For adoption, Oral explanation to be held on 16 July 2024 at 09:30

2.1.2. - EMA/OD/0000173345

   Treatment of AL amyloidosis

   **Action:** For adoption, Oral explanation to be held on 17 July 2024 at 15:30

2.1.3. - EMA/OD/0000173347

   Treatment of ATTR amyloidosis

   **Action:** For adoption, Oral explanation to be held on 17 July 2024 at 15:30

2.1.4. - EMA/OD/0000169543

   Treatment of chronic pancreatitis

   **Action:** For adoption, Oral explanation to be held on 18 July 2024 at 08:45

2.1.5. - EMA/OD/0000164952

   Treatment of complex regional pain syndrome

   **Action:** For adoption, Oral explanation to be held on 17 July 2024 at 17:15
2.1.6. - EMA/OD/0000172086
Treatment of punctate palmoplantar keratoderma
Action: For adoption, Oral explanation to be held on 16 July 2024 at 16:30

2.1.7. - EMA/OD/0000166750
Treatment of epidermolysis bullosa
Action: For adoption, Oral explanation to be held on 16 July 2024 at 14:30

2.1.8. - EMA/OD/0000165577
Treatment of Fabry disease
Action: For adoption, Oral explanation to be held on 18 July 2024 at 11:00

2.2. For discussion / preparation for an opinion

2.2.1. - EMA/OD/0000154786
Prevention of arteriovenous access dysfunction in patients undergoing surgical creation of an arteriovenous fistula for haemodialysis
Action: For discussion/adoption

2.2.2. - EMA/OD/0000155550
Diagnosis of marginal zone lymphoma
Action: For discussion/adoption

2.2.3. - EMA/OD/0000160667
Treatment of anti-neutrophil cytoplasmic antibody (ANCA) – associated vasculitis (AAV)
Action: For discussion/adoption

2.2.4. - EMA/OD/0000167672
Treatment of small cell lung cancer
Action: For discussion/adoption

2.2.5. - EMA/OD/0000168913
Treatment of large-cell neuroendocrine carcinoma of the lung
Action: For discussion/adoption

2.2.6. - EMA/OD/0000168919
Treatment of extrapulmonary neuroendocrine carcinoma
<table>
<thead>
<tr>
<th>Action</th>
<th>EMA/OD</th>
</tr>
</thead>
<tbody>
<tr>
<td>For discussion/adoption</td>
<td></td>
</tr>
<tr>
<td><strong>2.2.7.</strong> Treatment of fungal keratitis</td>
<td>EMA/OD/0000168961</td>
</tr>
<tr>
<td><strong>2.2.8.</strong> Treatment of Wiskott Aldrich syndrome (WAS)</td>
<td>EMA/OD/0000169888</td>
</tr>
<tr>
<td><strong>2.2.9.</strong> Prevention of acute liver failure (ALF)</td>
<td>EMA/OD/0000170073</td>
</tr>
<tr>
<td><strong>2.2.10.</strong> Treatment of cystic fibrosis</td>
<td>EMA/OD/0000171663</td>
</tr>
<tr>
<td><strong>2.2.11.</strong> Treatment of glutaric aciduria</td>
<td>EMA/OD/0000171786</td>
</tr>
<tr>
<td><strong>2.2.12.</strong> Treatment of Wilson's disease</td>
<td>EMA/OD/0000173551</td>
</tr>
<tr>
<td><strong>2.2.13.</strong> Treatment of complex regional pain syndrome</td>
<td>EMA/OD/0000174349</td>
</tr>
<tr>
<td><strong>2.2.14.</strong> Treatment of chondrosarcoma</td>
<td>EMA/OD/0000174573</td>
</tr>
<tr>
<td><strong>2.2.15.</strong> Treatment of pouchitis</td>
<td>EMA/OD/0000178304</td>
</tr>
</tbody>
</table>
Action: For discussion/adoption

2.2.16. - EMA/OD/0000178496
Treatment of inborn errors of primary bile acid synthesis

Action: For discussion/adoption

2.2.17. - EMA/OD/0000178582
Treatment of pulmonary arterial hypertension

Action: For discussion/adoption

2.2.18. - EMA/OD/0000179126
Treatment of familial chylomicronemia syndrome (FCS)

Action: For discussion/adoption

2.2.19. - EMA/OD/0000179366
Treatment of pancreatic cancer

Action: For discussion/adoption

2.2.20. - EMA/OD/0000179561
Treatment of cutaneous T-cell lymphoma (CTCL)

Action: For discussion/adoption

2.2.21. - EMA/OD/0000183012
Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype

Action: For discussion/adoption

2.2.22. - EMA/OD/0000171163
Treatment of gastric cancer (including cancer of the gastro-oesophageal junction)

Action: For discussion/adoption

2.3. Revision of the COMP opinions
None

2.4. Amendment of existing orphan designations
None
2.5.  **Appeal**

None

2.6.  **Nominations**

2.6.1.  New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

**Action**: For adoption

OMPd applications - appointment of rapporteurs at the 16-18 July 2024 COMP meeting

2.7.  **Evaluation on-going**

None

3.  **Requests for protocol assistance with significant benefit question**

3.1.  **Ongoing procedures**

3.1.1.  -

Treatment of STXB1 developmental and epileptic encephalopathy

**Action**: For adoption

3.1.2.  -

Treatment of hereditary angioedema

**Action**: For adoption

3.1.3.  -

Treatment of primary sclerosing cholangitis

**Action**: For adoption

3.1.4.  -

Treatment of glioma

**Action**: For adoption

3.1.5.  -

Treatment of Dravet syndrome

**Action**: For adoption
4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

4.1.1. - odronextamab - EMEA/H/C/006215

Regeneron Ireland Designated Activity Company

a) Treatment of follicular lymphoma, EU/3/22/2649, EMA/OD/0000168564

**Action**: For adoption, Oral explanation to be held on 17 July 2024 at 09:00

b) Treatment of diffuse large B-cell lymphoma, EU/3/22/2656, EMA/OD/0000168574

**Action**: For adoption, Oral explanation to be held on 17 July 2024 at 09:00

4.1.2. Tepkinly - epcoritamab - EMEA/H/C/005985/II/0001, EU/3/22/2634, EMA/OD/0000157895

Abbvie Deutschland GmbH & Co. KG; Treatment of follicular lymphoma

**Action**: For adoption, Oral explanation to be held on 17 July 2024 at 11:30

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. - elafibranor - EMEA/H/C/006231/0000, EU/3/19/2182, EMA/OD/0000173044

Ipsen Pharma; Treatment of primary biliary cholangitis

**Action**: For information

4.2.2. - chimeric monoclonal antibody against claudin-18 splice variant 2 - EMEA/H/C/005868, EU/3/10/803, EMA/OD/0000166702

Astellas Pharma Europe B.V.; Treatment of gastric cancer

**Action**: For discussion/adoption, Oral explanation to be held on 17 July 2024 at 14:00

4.3. Appeal

None

4.4. On-going procedures

**Action**: For information

Review of orphan designation for OMP for MA - On-going procedures
4.5. **Orphan Maintenance Reports**

*Action*: For information

5. **Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension**

5.1. **After adoption of CHMP opinion**

None

5.2. **Prior to adoption of CHMP opinion**

5.2.1. Lutathera - lutetium (\(^{177}\)Lu) oxodotreotide - EMEA/H/C/004123/II/0052, EU/3/07/523

Advanced Accelerator; Treatment of gastro-entero-pancreatic neuroendocrine tumours

*Action*: For discussion/adoption

5.2.2. Ngenla - somatrogon - EMEA/H/C/005633/II/0016, EU/3/12/1087

Pfizer Europe MA EEIG; Treatment of Growth hormone deficiency

*Action*: For discussion/adoption

5.3. **Appeal**

None

5.4. **On-going procedures**

*Action*: For information

Review of orphan designation for OMP for MA extension - On-going procedures

6. **Application of Article 8(2) of the Orphan Regulation**

None

7. **Organisational, regulatory and methodological matters**

7.1. **Mandate and organisation of the COMP**

7.1.1. COMP membership

*Action*: For information
7.1.2. **Vote by proxy**

**Action:** For information

7.1.3. **Strategic Review & Learning meetings - Hungary**

Update on the SRLM meeting to be held during the upcoming Hungarian Presidency

**Action:** For information

7.1.4. **Protocol Assistance Working Group (PAWG)**

Proposed meeting time on 17 July 2024 at 12:50

PAWG draft agenda for 17 July 2024 meeting

7.1.5. **COMP Decisions Database**

**Action:** For discussion

7.2. **Coordination with EMA Scientific Committees or CMDh-v**

7.2.1. **Recommendation on eligibility to PRIME – report**

PRIME eligibility requests - list of adopted outcomes June 2024

7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

7.3.1. **Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)**

None

7.3.2. **Upcoming ITF meetings**

**Action:** For discussion

Upcoming ITF meetings

7.4. **Cooperation within the EU regulatory network**

7.4.1. **European Commission**

None

7.5. **Cooperation with International Regulators**

7.5.1. **Food and Drug Administration (FDA)**

None
7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

None

7.5.3. Therapeutic Goods Administration (TGA), Australia

None

7.5.4. Health Canada

None

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2024

**Action:** For information

7.8.2. Overview of orphan marketing authorisations/applications

**Action:** For information

8. Any other business

8.1. EMA business Pipeline activity

**Action:** For information

Q2-2024 Update of the Business Pipeline report for the human scientific committees

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

**Abbreviations / Acronyms**

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products
EC: European Commission
OD: Orphan Designation
PA: Protocol Assistance
PDCO: Paediatric Committee
PRAC: Pharmacovigilance and Risk Assessment Committee
SA: Scientific Advice
SAWP: Scientific Advice Working Party

**Orphan Designation (section 2 Applications for orphan medicinal product designation)**

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

**Protocol Assistance (section 3 Requests for protocol assistance with significant benefit question)**

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

**Maintenance of Orphan Designation (section 4 Review of orphan designation for orphan medicinal products for marketing authorisation).**

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

For a list of acronyms and abbreviations, see:

[Abbreviations used in EMA scientific committees & CMD documents and in relation to EMA’s regulatory activities](www.ema.europa.eu/)

More detailed information on the above terms can be found on the EMA website: